[Clinical and hemodynamic effects of captopril in patients with chronic circulatory failure].
The effect of a new drug, captopril, an inhibitor of the enzyme responsible for the conversion of angiotensin I to angiotensin II, were examined in 15 patients with chronic circulatory insufficiency in the presence of coronary heart disease. The efficiency of single doses and four-week courses of the drug was assessed. Captopril was shown to reduce significantly pulmonary arterial occlusion pressure and total peripheral resistance and increase the minute volume, thus improving left-ventricular function. Considering good tolerance of the drug, it can be recommended for the treatment of chronic circulatory insufficiency.
D000328:Adult; D000368:Aged; D002216:Captopril / Q000627:therapeutic use*; D002908:Chronic Disease; D003327:Coronary Disease / Q000150:complications; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D013997:Time Factors
D002216:Captopril
Klinicheskie i gemodinamicheskie éffekty kaptoprila u bol'nykh s khronicheskoĭ nedostatochnost'iu krovoobrashcheniia.